Publications

2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal del Castillo T, Rodríguez-Macías G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. New England Journal Of Medicine 2026, 394 DOI: 10.1056/NEJMoa2510223.
Peer-Reviewed Original Research
This study investigates the safety and efficacy of an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed acute myeloid leukemia, showing a 47% complete response rate and improved survival with manageable side effects.
Full Summary
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.
Peer-Reviewed Original Research
This study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.
Full Summary
PIP4K2A/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC
He Z, Chen S, Bosenberg M, Muthusamy V, Xi Y, Wang H, Micheli F, Cianciulli A, Beato C, Van Zandt M, Ellman J, Ha Y. PIP4K2A/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC. IScience 2026, 29: 115952. DOI: 10.1016/j.isci.2026.115952.
Peer-Reviewed Original Research
Concepts
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.
Burtness B, Rosenberg AJ, Calderon B, Lim SM, Yang MH, Li SH, Kadowaki S, Swiecicki PL, Geiger JL, Ince W, Hahn D, Guo Y, Adkins D, Metcalf R, Ahn MJ, Sukari A, Braña I, Keam B, Tanaka H, Sheth S, Oliva M, Lyu X, Curtin JC, Toyoizumi K, Xie J, Wade M, Diorio B, Kapoor A, Yilmaz E, Baig M, Kim P, Verheijen RB, Shah S, Harrington KJ. Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. J Clin Oncol 2026, 101200JCO2601042. PMID: 42218660, DOI: 10.1200/JCO-26-01042.
Peer-Reviewed Original Research
This study investigates amivantamab in recurrent/metastatic head and neck cancer, showing a 42% response rate and durable antitumor activity after prior immunotherapy and chemotherapy.
Full Summary
Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds
Wang D, Sra M, Ng D, Tadepalli A, Rinaldi K, Ito S, Cuker A, Goshua G. Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds. Blood Advances 2026 PMID: 42206692, DOI: 10.1182/bloodadvances.2026020143.
Peer-Reviewed Original Research
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.
Ge X, Singh J, Li W, Markham CS, Ruiz CF, Stites EC, Bhattacharyya M, Liu Y, Muzumdar MD. PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer Res 2026 PMID: 42095550, DOI: 10.1158/0008-5472.CAN-25-3625.
Peer-Reviewed Original Research
This study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.
Full Summary
Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.
Peer-Reviewed Original Research
This study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.
Full Summary
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
Braun DA, Noel MS, Moy RH, Demel K, Gutierrez M, Sharma S, Hussain A, Gadgeel S, Peguero J, Choueiri TK, Emamekhoo H, Van Tine B, Balaraman R, Elliott G, Nath S, Daigle SR, Kumar P, Scheuber A, Sommerhalder D. HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. Cell Reports Medicine 2026, 102789. DOI: 10.1016/j.xcrm.2026.102789.
Peer-Reviewed Original Research
Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State
Ninia JG, Verma N, Long JB, Laird JH, Hicks DF, Hayman TJ, Knowlton CA, Campbell AM, Housri N, Peters GW, Al Feghali KA, de Jong D, Chiang AC, Park HS. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State. Clinical Lung Cancer 2026, 27 DOI: 10.1016/j.cllc.2026.03.009.
Peer-Reviewed Original Research
County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care.
Gaddy JJ, Lee DH, Herrin J, Yu JB, Pollack CE, Dean LT, Dougherty GB, Canavan ME, Soulos PR, Gross CP. County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care. JAMA Netw Open 2026, 9: e2613919. PMID: 42160049, DOI: 10.1001/jamanetworkopen.2026.13919.
Peer-Reviewed Original Research
This study investigates how structural racism at the county level impacts racial disparities in lung cancer care, showing worse outcomes for Black patients compared to white patients, especially in areas with higher structural racism.
Full Summary
Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas.
Ruiz C, Ge X, McDonnell R, Agabiti S, McQuaid D, Tang A, Kharwa M, Goodell J, Saavedra-Pena R, Wing A, Li G, Medici N, Robert M, Varshney R, Rudolph M, Gorelick F, Wysolmerski J, Canals D, Haley J, Rodeheffer M, Muzumdar M. Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. Cancer Discovery 2026 PMID: 42053430, DOI: 10.1158/2159-8290.cd-25-0734.
Peer-Reviewed Original Research
This study investigates how dietary fat composition influences pancreatic cancer, showing that monounsaturated fats promote tumor growth while polyunsaturated fats reduce risk by enhancing ferroptosis sensitivity.
Full Summary
Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia
Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.
Peer-Reviewed Original Research
This study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis.
Full Summary
Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks
Dai J, Posta M, Marczyk M, Qing T, Gyorffy B, Pusztai L. Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks. Genome Medicine 2026, 18: 59. PMID: 42057121, PMCID: PMC13151107, DOI: 10.1186/s13073-026-01644-8.
Peer-Reviewed Original Research
Concepts
Bispecific targeting of CHI3L1 and PD-1 as a therapeutic strategy for pulmonary fibrosis
Jeong H, Sadanaga T, Lee J, Kamle S, Ma B, Zhou Y, Shin S, Elias J, Lee C. Bispecific targeting of CHI3L1 and PD-1 as a therapeutic strategy for pulmonary fibrosis. JCI Insight 2026 PMID: 42048160, DOI: 10.1172/jci.insight.201609.
Peer-Reviewed Original Research
Concepts
Evolving therapeutics in colorectal cancer peritoneal metastases
Bader J, Aguirre N, Schultz K, Ofori K, Godfrey E, Gupta P, Tseng R, Cecchini M, Sundar R, Turaga K. Evolving therapeutics in colorectal cancer peritoneal metastases. Cancer And Metastasis Reviews 2026, 45: 25. PMID: 42024175, DOI: 10.1007/s10555-026-10335-0.
Peer-Reviewed Original Research
MeSH Keywords
Motivation to Participate in a Nutrition and Physical Activity Intervention During Chemotherapy for Breast Cancer: A Qualitative Study
Puklin L, Harrigan M, McGowan C, Ferrucci L, Cartmel B, Zupa M, Deyling M, Sanft T, Sharifi M, Irwin M. Motivation to Participate in a Nutrition and Physical Activity Intervention During Chemotherapy for Breast Cancer: A Qualitative Study. Psycho-Oncology 2026, 35: e70472. PMID: 42025931, PMCID: PMC13106104, DOI: 10.1002/pon.70472.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma.
He M, Trontzas I, Bates K, Burela S, Moutafi M, Ahmed F, Shafi S, Robbins C, Liebler D, Fulton R, Burtness B, Rimm D. Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics 2026, of1-of10. PMID: 42008736, DOI: 10.1158/1535-7163.mct-25-1456.
Peer-Reviewed Original Research
Concepts
Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States
Lee D, Li Y, Yang S, Chiang A, Soulos P, Gross C, Wang S. Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States. Cancer Medicine 2026, 15: e71736. PMID: 42007970, PMCID: PMC13094514, DOI: 10.1002/cam4.71736.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab
Savion-Gaiger N, Perales O, Su D, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open 2026, 11: 106908. PMID: 42013628, PMCID: PMC13123346, DOI: 10.1016/j.esmoop.2026.106908.
Peer-Reviewed Original Research
This study investigates biomarkers in renal cell carcinoma, showing tumor PD-L1 expression predicts better survival with immunotherapy, while neutrophil markers highlight sarcomatoid/rhabdoid tumor immune environments.
Full Summary
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.
Harding JJ, Hofheinz R, Élez E, Kuboki Y, Rasco DW, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Haderk F, Mészáros L, Wölke S, Katakabe T, Lorence RM, Van Cutsem E, Kopetz S, Pant S. BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. Cancer Res Commun 2026 PMID: 41987415, DOI: 10.1158/2767-9764.CRC-25-0638.
Peer-Reviewed Original Research
Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry
Pine A, Butt A, Andreoli L, Knight J, Gerosa M, Cecchi I, Branch D, Lopez-Pedrera R, Belmont H, Kello N, Petri M, Cervera R, Pengo V, Meroni P, Cohen H, Willis R, Bertolaccini M, Goshua G, Gu S, Hwa J, Lee A, Erkan D, Sharda A. Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry. Frontiers In Immunology 2026, 17: 1807468. DOI: 10.3389/fimmu.2026.1807468.
Peer-Reviewed Original Research
Concepts
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Mohty R, Narra R, Mims A, Hunter C, Shallis R, Kota V, Jamy O, Coltoff A, Othman T, Jonas B, Patel A, DuVall A, Foucar C, Abdelsamia M, Palmisiano N, Patel S, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2026, ahead-of-print: 1-8. PMID: 41954351, DOI: 10.1080/10428194.2026.2650679.
Peer-Reviewed Original Research
This study investigates predictors of complete molecular response (CMR) and shows that early CMR improves relapse-free survival in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
Full Summary
Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer
Mihailescu M, Fish A, Madoff D. Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer. Cancers 2026, 18: 1189. DOI: 10.3390/cancers18081189.
Peer-Reviewed Original Research
This study investigates advances in minimally invasive therapies for lung cancer, showing improved tumor targeting, safety, and potential benefits when combined with immunotherapy and chemotherapy.
Full Summary
In Reply to: “Response to Intra-arterial Chemotherapy in Patients with Adenoid Cystic Carcinoma of Lacrimal Gland”
Costa P, Tse D, Benedetto P. In Reply to: “Response to Intra-arterial Chemotherapy in Patients with Adenoid Cystic Carcinoma of Lacrimal Gland”. The Oncologist 2026, oyag087. PMID: 41955416, DOI: 10.1093/oncolo/oyag087.
Peer-Reviewed Original Research
Concepts
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
Stockhammer P, El Zarif T, Schillo JL, Li F, Goldberg SB, Politi K, Grant MJ. ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. J Thorac Oncol 2026, 103708. PMID: 41932614, DOI: 10.1016/j.jtho.2026.103708.
Peer-Reviewed Original Research

See All Publications